Inclusion Criteria:

   - The patient must be enrolled on a frontline COG therapeutic trial for treatment of a
   primary malignancy and is nearing completion of or has recently completed protocol
   treatment (within the past 180 days)*; or the patient must have been enrolled on a COG
   (or Legacy Group) therapeutic or non-therapeutic trial targeted for long-term
   follow-up by ALTE05N1

      - Hodgkin lymphoma

         - CCG 5942

         - POG 9425

         - POG 9426

         - AHOD0031

      - Brain tumor

         - A9961

      - Acute lymphoblastic leukemia

         - POG 9404

      - Osteosarcoma

         - POG 9754

      - Stem cell transplantation

         - ASCT0631D

      - Rhabdomyosarcoma

         - IRS-III

         - IRS-IV

      - Note: For purposes of enrollment onto this study, completion of treatment is
      defined as the date protocol therapy was terminated as reported (or will be
      reported) on this patient?s last ?Reporting Period Worksheet/CRF? for their
      frontline therapeutic protocol; patients become eligible as they approach this
      date, and remain eligible for 180 days following the date that protocol therapy
      was terminated; early termination of protocol therapy per the decision of the
      patient, family and/or investigator does NOT preclude enrollment on this study

      - Note: For purposes of eligibility for ALTE05N1, ?early termination of protocol
      therapy? means that the patient has finished protocol therapy and will not
      receive further treatment; patients whose therapy is terminated early due to
      toxicity or who opt out of an end-of-therapy randomization (e.g., randomization
      to continue with an experimental agent versus [vs.] no further treatment) are
      eligible because they will not be receiving further therapy; however, a patient
      who is removed from protocol therapy or opts to discontinue protocol
      participation early in the course of treatment (e.g., following Induction) is not
      eligible

   - The patient must reside in the U.S. on the date of enrollment to ALTE05N1

   - All patients and/or their parents or legal guardians must sign a written informed
   consent

   - All institutional, Food and Drug Administration (FDA), and National Cancer Institute
   (NCI) requirements for human studies must be met